Alterity Therapeutics (ATHE) Net Income towards Common Stockholders (2016 - 2019)

Alterity Therapeutics has reported Net Income towards Common Stockholders for 4 years, with the latest figure at -$3.9 million in Q4 2019.

• For the quarter ending Q4 2019, Net Income towards Common Stockholders fell 0.58% year-over-year to -$3.9 million; the trailing twelve-month figure through Jun 2021 stood at -$3.9 million (up 49.85% YoY), and the FY2025 full-year result was -$7.8 million, up 38.27% from the prior year.
• Net Income towards Common Stockholders for Q4 2019 stood at -$3.9 million, down from -$3.8 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$2.7 million in Q4 2016, with the low at -$3.9 million in Q4 2019.
• Average Net Income towards Common Stockholders over 4 years is -$3.3 million, with a median of -$3.3 million recorded in 2017.
• Year-over-year, Net Income towards Common Stockholders tumbled 37.71% in 2018 and decreased 0.58% in 2019.
• Tracing ATHE's Net Income towards Common Stockholders over 4 years: stood at -$2.7 million in 2016, then declined by 1.55% to -$2.8 million in 2017, then tumbled by 37.71% to -$3.8 million in 2018, then declined by 0.58% to -$3.9 million in 2019.
• The last three Net Income towards Common Stockholders figures came in at -$3.9 million (Q4 2019), -$3.8 million (Q4 2018), and -$2.8 million (Q4 2017), per Business Quant data.

Peer Comparison